Home / Stock ratings / Healthcare Stocks / PFE
Stock rating · Pharmaceutical Preparations
Pfizer Inc. (PFE) Stock Rating & Analysis
As of October 7, 2026, MELANY rates Pfizer Inc. 66 out of 100 (Favorable). Its highest factor score is earnings track record at 92, and its lowest is macro fit at 50.
MELANY ratingRated 2026-10-07PFE · composite score
About Pfizer Inc.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. Once a maker of many types of healthcare products and chemicals, it now derives most sales from prescription drugs and vaccines, with top sellers including the pneumococcal vaccine Prevnar 13 and the cardiology drugs Vyndaqel and Eliquis; it sells globally, with international sales 40% of the total and emerging markets a major contributor.
Rating as of 2026-10-07 · this is a dated snapshot; the live rating is in the app (Pro, free for 30 days). The price above updates in real time.
How PFE's rating has moved
- -5Past week, since Sep 30: score fell 5 points to 66.
- -3Past four weeks, since Sep 9: score fell 3 points to 66.
Weekly points: Sep 9: 69 · Sep 16: 69 · Sep 23: 70 · Sep 30: 71 · Oct 7: 66 (this page).
From MELANY's own dated rating record. A tier change is reported as a move between named tiers; the score carries the direction.
Why PFE scores 66/100
PFE's 8 factor scores run from 50 to 92, and 2 of them sit above its composite of 66. Here is how PFE breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- Forward P/E 9.5x, earnings growth accelerating
- FCF yield 8.0%
Margins, returns on capital, and balance-sheet strength.
- Gross margin 75%
Direction and relative strength of the recent share-price trend.
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 4 of last 4 quarters
- Avg EPS beat +16%
- Earnings in 27 days (strong beat history)
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
- Earnings in 27 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How PFE compares
As of October 7, 2026, Pfizer Inc. is tied for 12th of 20 in Healthcare Stocks, where the average score is 67.
Key risks for PFE
- No specific company-level red flags detected, monitor macro regime changes
Sector and theme context
Pfizer Inc. sits in the Healthcare sector theme, which MELANY currently rates 37/100 for strength. Theme strength feeds PFE's momentum and catalyst factors above.
PFE trade plan (Pro)
MELANY has a full position plan for Pfizer Inc.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.
How MELANY rates PFE
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Pfizer Inc.'s 66/100 reflects mature factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about PFE
Is Pfizer Inc. (PFE) a buy?
As of 2026-10-07, MELANY rated Pfizer Inc. Favorable with a composite score of 66/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Pfizer Inc.'s MELANY score?
Pfizer Inc. (PFE) has a MELANY composite score of 66/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the PFE stock rating calculated?
MELANY scores PFE from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Pfizer Inc. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Pfizer Inc. (PFE) Favorable with a composite of 66/100 as of 2026-10-07. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the PFE stock price forecast?
MELANY does not publish price targets or forecasts for PFE. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 66/100 across eight factors for Pfizer Inc., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is PFE stock overvalued or undervalued?
MELANY's valuation factor currently reads 63/100 for Pfizer Inc., where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives PFE's read.
What price should I buy PFE at?
Rather than chasing the current price, MELANY computes a smart entry zone for PFE: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.
What are the risks of buying PFE stock?
The top risks MELANY currently flags for Pfizer Inc.: No specific company-level red flags detected, monitor macro regime changes. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Pfizer Inc. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 67/100 for Pfizer Inc., and earnings track record, at 92/100. The 66/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will PFE stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 55/100 for PFE right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this PFE rating?
The rating on this page is a snapshot of MELANY's read as of 2026-10-07. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores PFE continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, PFE included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.